JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on July 16, 2007; DOI: 10.1124/jpet.107.123638


0022-3565/07/3231-85-93$20.00
JPET 323:85-93, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.107.123638v1
323/1/85    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vaziri, N. D.
Right arrow Articles by Rodriguez-Iturbe, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vaziri, N. D.
Right arrow Articles by Rodriguez-Iturbe, B.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Kidney Diseases

GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Intra-Renal Angiotensin II/AT1 Receptor, Oxidative Stress, Inflammation, and Progressive Injury in Renal Mass Reduction

N. D. Vaziri, Y. Bai, Z. Ni, Y. Quiroz, R. Pandian, and B. Rodriguez-Iturbe

Division of Nephrology and Hypertension, University of California, Irvine, California (N.D.V., Y.B., Z.N., R.P.); and Renal Service, Hospital Universitario, Universidad del Zulia and Centro de Investigaciones Biomédicas, IVIC-Zulia, Maracaibo, Venezuela (Y.Q., B.R.-I.)

Significant reduction of renal mass triggers a chain of events that result in glomerular hypertension/hyperfiltration, proteinuria, glomerulosclerosis, tubulointerstitial injury, and end-stage renal disease. These events are mediated by a constellation of hemodynamic, oxidative, and inflammatory reactions that are, in part, driven by local AT1 receptor (AT1r) activation by angiotensin II (Ang II). Here we explored the effects of 5/6 nephrectomy with and without AT1r blockade (losartan for 8 weeks) on AT1r and AT2r and Ang II-positive cell count, pathways involved in oxidative stress and inflammation [NAD(P)H oxidase, nuclear factor {kappa}B (NF{kappa}B), 12-lipooxygenase, cyclooxygenase (COX)-1, COX-2, monocyte chemoattractant protein (MCP)-1, plasminogen activator inhibitor (PAI)-1, renal T cell, and macrophage infiltration] as well as renal function and structure. The untreated group exhibited hypertension, deterioration of renal function and structure, reduced or unchanged plasma renin activity, aldosterone concentration, marked up-regulations of AT1r (250%), Ang II-expressing cell count (>20-fold), NAD(P)H oxidase subunits (gp91phox, p22phox, and P47phox; 20–40%), COX-2 (250%), 12-lipooxygenase (100%), MCP-1 (400%), and PAI-1 (>20-fold), activation of NF{kappa}B, and interstitial infiltrations of T cells and macrophages in the remnant kidneys. AT1r blockade attenuated the biochemical and histological abnormalities, prevented hypertension, and decelerated deterioration of renal function and structure. Thus, the study demonstrated a link between up-regulation of Ang II/AT1r system and oxidative stress, inflammation, hypertension, and progression of renal disease in rats with renal mass reduction.


Received April 3, 2007; accepted July 13, 2007.

Address correspondence to: Dr. Nosratola D. Vaziri, MACP, Division of Nephrology and Hypertension, UCI Medical Center, 101 The City Drive, Bldg. 53, Rm. 125, Rt. 81, Orange, CA 92868. E-mail: ndvaziri{at}uci.edu




This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
K.-h. Cho, H.-j. Kim, B. Rodriguez-Iturbe, and N. D. Vaziri
Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure
Am J Physiol Renal Physiol, July 1, 2009; 297(1): F106 - F113.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
H. J. Kim, H. Moradi, J. Yuan, K. Norris, and N. D. Vaziri
Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney
Am J Physiol Renal Physiol, June 1, 2009; 296(6): F1297 - F1306.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
S. S. Ghosh, H. D. Massey, R. Krieg, Z. A. Fazelbhoy, S. Ghosh, D. A. Sica, I. Fakhry, and T. W. B. Gehr
Curcumin ameliorates renal failure in 5/6 nephrectomized rats: role of inflammation
Am J Physiol Renal Physiol, May 1, 2009; 296(5): F1146 - F1157.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
G. Piecha, N. Koleganova, M.-L. Gross, A. Geldyyev, M. Adamczak, and E. Ritz
Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination
Am J Physiol Renal Physiol, July 1, 2008; 295(1): F137 - F144.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
Y. Quiroz, A. Ferrebuz, F. Romero, N. D. Vaziri, and B. Rodriguez-Iturbe
Melatonin ameliorates oxidative stress, inflammation, proteinuria, and progression of renal damage in rats with renal mass reduction
Am J Physiol Renal Physiol, February 1, 2008; 294(2): F336 - F344.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.